Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 15/20 | 0.65 |
| ▸ | CCNC | P24863 | 3/20 | 0.39 |
| ▸ | CDK8 | P49336 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21859069 | 0.88 | CHRM1 (0.65) | CHRM1CCNCCDK8 | |
| SCHEMBL22322560 | 0.84 | CHRM1 (0.55) | CHRM1CNR1 | |
| SCHEMBL21859057 | 0.84 | CHRM1 (0.70) | CHRM1CCNCCDK8 | |
| SCHEMBL22322439 | 0.83 | CHRM1 (0.71) | CHRM1CCNCCDK8 | |
| SCHEMBL21858935 | 0.82 | CHRM1 (0.68) | CHRM1CCNCCDK8 | |
| SCHEMBL21938242 | 0.82 | CHRM1 (0.75) | CHRM1CCNCCDK8 | |
| SCHEMBL21859103 | 0.79 | CHRM1 (1.00) | CHRM1 | |
| SCHEMBL21859079 | 0.79 | CHRM1 (0.64) | CHRM1CCNCCDK8 | |
| SCHEMBL21858936 | 0.78 | CHRM1 (1.00) | CHRM1 | |
| SCHEMBL21859009 | 0.78 | CHRM1 (0.67) | CHRM1CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122779-B2 | Pyrrolo-pyridazine derivatives as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2024-10-22 | — | — | US | claimed |
| CN-113166160-B | Pyrrolopyridazine derivatives as modulators of the positive allosteric of the muscarinic M1 receptor | 苏文生命科学有限公司 | 2023-12-19 | — | — | CN | claimed |
| EP-3867254-B1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-05-31 | — | — | EP | claimed |
| US-20210340148-A1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-11-04 | — | — | US | claimed |
| CN-113166160-A | Pyrrolopyridazine derivatives as positive allosteric modulators of muscarinic M1 receptors | 苏文生命科学有限公司 | 2021-07-23 | — | — | CN | claimed |
| WO-2020079606-A9 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-08-13 | — | — | WO | claimed |
| WO-2020079606-A1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-04-23 | — | — | WO | claimed |
| US-12122779-B2 | Pyrrolo-pyridazine derivatives as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2024-10-22 | — | — | US | disclosed |
| CN-113166160-B | Pyrrolopyridazine derivatives as modulators of the positive allosteric of the muscarinic M1 receptor | 苏文生命科学有限公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-3867254-B1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-05-31 | — | — | EP | disclosed |
| EP-3867254-B1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-05-31 | — | — | EP | disclosed |
| US-20210340148-A1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-11-04 | — | — | US | disclosed |
| US-20210340148-A1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-11-04 | — | — | US | disclosed |
| CN-113166160-A | Pyrrolopyridazine derivatives as positive allosteric modulators of muscarinic M1 receptors | 苏文生命科学有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020079606-A9 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020079606-A1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340148-A1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM5, CHRM2 | CHRM1 1/4885CCNC 3339/4885CDK8 2256/4885 |
| US-12122779-B2 | Pyrrolo-pyridazine derivatives as muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM5, CHRM2 | CHRM1 1/4885CCNC 3339/4885CDK8 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.